Turnitin
降AI改写
早检测系统
早降重系统
Turnitin-UK版
万方检测-期刊版
维普编辑部版
Grammarly检测
Paperpass检测
checkpass检测
PaperYY检测
Epidemiology of acute myeloid leukemia: Recent progress and enduring challenges
RM Shallis, R Wang, A Davidoff, X Ma, AM Zeidan - Blood reviews, 2019 - Elsevier
Acute myeloid leukemia (AML) is a malignant disorder of the bone marrow which is
characterized by the clonal expansion and differentiation arrest of myeloid progenitor cells …
characterized by the clonal expansion and differentiation arrest of myeloid progenitor cells …
Targeting FLT3 mutations in AML: review of current knowledge and evidence
Genomic investigations of acute myeloid leukemia (AML) have demonstrated that several
genes are recurrently mutated, leading to new genomic classifications, predictive …
genes are recurrently mutated, leading to new genomic classifications, predictive …
The clinical impact of the molecular landscape of acute myeloid leukemia
S Kayser, MJ Levis - Haematologica, 2023 - pmc.ncbi.nlm.nih.gov
Research into the underlying pathogenic mechanisms of acute myeloid leukemia (AML) has
led to remarkable advances in our understanding of the disease. Mutations now allow us to …
led to remarkable advances in our understanding of the disease. Mutations now allow us to …
Research progress on dendritic cell vaccines in cancer immunotherapy
J Yu, H Sun, W Cao, Y Song, Z Jiang - Experimental hematology & …, 2022 - Springer
Dendritic cell (DC) vaccines induce specific immune responses that can selectively
eliminate target cells. In recent years, many studies have been conducted to explore DC …
eliminate target cells. In recent years, many studies have been conducted to explore DC …
Venetoclax with azacitidine or decitabine in patients with newly diagnosed acute myeloid leukemia: long term follow‐up from a phase 1b study
This analysis represents the longest‐term follow‐up for patients with acute myeloid leukemia
(AML) treated with 400 mg of venetoclax plus azacitidine or decitabine. Adults with newly …
(AML) treated with 400 mg of venetoclax plus azacitidine or decitabine. Adults with newly …
Acute myeloid leukemia: 2019 update on risk‐stratification and management
EH Estey - American journal of hematology, 2018 - Wiley Online Library
Outcome in patients with acute myeloid leukemia (AML) ranges from death within a few days
of beginning treatment (treatment related mortality, TRM) to likely cure. The major reason …
of beginning treatment (treatment related mortality, TRM) to likely cure. The major reason …
Measurable residual disease at induction redefines partial response in acute myeloid leukemia and stratifies outcomes in patients at standard risk without NPM1 …
Purpose We investigated the effect on outcome of measurable or minimal residual disease
(MRD) status after each induction course to evaluate the extent of its predictive value for …
(MRD) status after each induction course to evaluate the extent of its predictive value for …
[HTML][HTML] CD123 as a therapeutic target in the treatment of hematological malignancies
The interleukin-3 receptor alpha chain (IL-3Rα), more commonly referred to as CD123, is
widely overexpressed in various hematological malignancies, including acute myeloid …
widely overexpressed in various hematological malignancies, including acute myeloid …
FLT3 inhibitors in acute myeloid leukemia: challenges and recent developments in overcoming resistance
Z Wang, J Cai, J Cheng, W Yang, Y Zhu… - Journal of Medicinal …, 2021 - ACS Publications
Mutations in the FMS-like tyrosine kinase 3 (FLT3) gene are often present in newly
diagnosed acute myeloid leukemia (AML) patients with an incidence rate of approximately …
diagnosed acute myeloid leukemia (AML) patients with an incidence rate of approximately …
CDK9 inhibitors in acute myeloid leukemia
Current treatment for acute myeloid leukemia (AML) is less than optimal, but increased
understanding of disease pathobiology and genomics has led to clinical investigation of …
understanding of disease pathobiology and genomics has led to clinical investigation of …